SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition Academic Article uri icon

Overview

MeSH Major

  • Neoplastic Cells, Circulating
  • Neuroendocrine Tumors
  • Prostatic Neoplasms

abstract

  • Using next-generation RNA sequencing and our newly developed bioinformatics tool, we identified a neuroendocrine prostate cancer (NEPC)-specific RNA splicing signature that is predominantly controlled by serine/arginine repetitive matrix 4 (SRRM4). We confirmed that SRRM4 drives NEPC progression, and we propose SRRM4 as a potential therapeutic target for NEPC.

publication date

  • January 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.eururo.2016.04.028

PubMed ID

  • 27180064

Additional Document Info